PT-141 (Bremelanotide): the complete guide

Bremelanotide is a synthetic cyclic heptapeptide. Short version: seven amino acids in a ring, engineered from alpha-melanocyte-stimulating hormone (α-MSH), the same family of signaling molecules that controls skin pigmentation, appetite, and - as it turns out - sexual motivation in the brain.

The compound started life as Melanotan II, a tanning agent developed at the University of Arizona in the 1990s. Researchers noticed something unexpected in early human trials: male volunteers kept reporting spontaneous erections. That side effect became the lead indication. Palatin Technologies spun out bremelanotide as a sexual-function drug, ran it through two decades of clinical development, and got it across the FDA finish line in June 2019.

The approved product is Vyleesi: a 1.75 mg subcutaneous autoinjector for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). That's the legal indication. Everything else you've read about PT-141 - for men, for postmenopausal women, as nasal spray, as troches - is off-label, compounded, or both.

Most sexual-function drugs work in the bloodstream. Bremelanotide works in the brain.

PT-141 is a non-selective agonist at melanocortin receptors - five subtypes, labeled MC1R through MC5R. At therapeutic doses the action concentrates at MC3R and MC4R. MC4R is the one that matters most. It's densely expressed in the medial preoptic area of the hypothalamus, a region neuroscientists have spent forty years linking to sexual motivation in mammals.

The cascade goes like this. Bremelanotide binds MC4R presynaptically. That stimulates dopamine release into the mesolimbic reward pathway and back into the preoptic area itself. Dopamine is the desire signal. In women, norepinephrine and oxytocin get pulled into the loop as well, which is the arousal side of the response.

In men, something additional happens downstream. MC3R and MC4R activation triggers local nitric oxide release in penile tissue, which produces vasodilation and erection. This is mechanistically distinct from how sildenafil works - Viagra blocks the enzyme that breaks down cGMP after nitric oxide is already present. Bremelanotide initiates the nitric oxide signal upstream, from the central nervous system. The two drugs can theoretically stack, and one Phase 2 program is testing exactly that.

MC1R, the pigmentation receptor, mediates the drug's most-discussed adverse effect: focal hyperpigmentation, more on this below.

Pharmacokinetics are tidy. Subcutaneous injection hits 100% bioavailability. Onset runs 30 to 60 minutes. Terminal half-life is about 2.7 hours. The cardiovascular effects - small, transient blood pressure rises - resolve inside twelve hours.

The clinical-development story matters because it shapes how the drug got labeled.

Palatin ran two key Phase 3 trials in parallel, both 24 weeks, both double-blind and placebo-controlled, both in premenopausal women diagnosed with HSDD. They were called RECONNECT 301 (NCT02333071) and RECONNECT 302 (NCT02338960). Together they enrolled 1,267 women. The FDA reviewed the combined dataset and approved Vyleesi on June 21, 2019.

The label is narrow on purpose. Premenopausal women only. Acquired and generalized HSDD - meaning the loss of desire has to be a change from baseline (not lifelong) and not situation-specific (not just "with this partner"). Uncontrolled hypertension and known cardiovascular disease are contraindications. No more than one dose per 24 hours, and no more than roughly eight per month.

Commercial history has been bumpier than the regulatory one. AMAG Pharmaceuticals launched Vyleesi, then divested. The rights moved through Cosette Pharmaceuticals and back toward Palatin's commercial arm. Sales never matched the projections. The drug exists, it's available, but it never became a household name the way Addyi briefly tried to.

The headline numbers from the integrated Phase 3 analysis: 58.3% of women on bremelanotide met the responder threshold for improved desire, against 36.1% on placebo, in Study 301. Study 302 replicated almost exactly - 58.2% vs 35.4%.

Both co-primary endpoints - the desire domain of the Female Sexual Function Index, and the distress score on the FSDS-DAO - cleared statistical significance (p<0.001) in both trials. Effect size for desire improvement landed around 0.39 in the pooled analysis. That's modest by drug-trial standards. It's also real.

The honest read is this: bremelanotide moves the needle on a condition that, for two decades, had almost nothing to offer.

A 52-week open-label extension followed the double-blind phase. Efficacy held. No new safety signals showed up. About 70% of women on bremelanotide elected to continue into the extension, against 87% of women on placebo - a gap that probably reflects the side-effect burden (more on nausea in a moment) rather than a failure of efficacy.

Subgroup analyses, published in 2022, looked at whether the response varied by age, BMI, weight, or bioavailable testosterone. It didn't. The drug worked across prespecified subgroups, which is unusual for sexual-function trials and worth noting.

HSDD is a real diagnosis with strict criteria. The DSM-5 reorganized it into "female sexual interest/arousal disorder," but the FDA still uses the HSDD framework for labeling purposes. Acquired and generalized means: the patient previously had normal desire and now doesn't, and the loss isn't tied to a specific partner, situation, or stimulus. It has to cause distress. And it has to not be better explained by relationship problems, untreated depression, a medication side effect, or a medical condition.

A lot of women who think they have HSDD don't, in the strict sense. A lot of clinicians don't screen for it carefully. Both facts matter for how this drug actually gets used.

For a patient who does meet criteria, Vyleesi is one of two FDA-approved options, the other being flibanserin (Addyi). The choice between them is non-trivial, and the next section gets to it.

Here's where the gap between marketing and evidence opens up.

Bremelanotide is not FDA-approved for men. The clinical evidence in men is older, smaller, and weaker than the women's program. The strongest data come from a Phase 2 intranasal study in men with sildenafil-responsive erectile dysfunction, which showed statistically real erectile response above 7 mg intranasal, onset around 30 minutes. A small follow-up combined intranasal PT-141 (7.5 mg) with sildenafil and reported prolonged penile rigidity over a 2.5-hour monitoring window.

Then the program went quiet for years. Palatin restarted a Phase 2 program in 2023 testing bremelanotide co-administered with a PDE5 inhibitor in men who don't respond to PDE5 inhibitors alone. Target enrollment is around 50 patients. Results haven't published.

The most-cited "real-world" data in men come from a 2024 observational survey by the Goldstein group covering 21 men using subcutaneous bremelanotide on an as-needed basis. Patients reported improvements in libido, ED, and orgasmic function. Twenty-one men. Open-label. No placebo arm.

That's the evidence base. Telehealth providers selling PT-141 to men are selling it on that.

To be clear: the drug almost certainly does something in men. The mechanism is biologically coherent and the early signals are directionally consistent. But "something" and "a randomized trial showed X% improvement over placebo" are not the same thing, and patients buying PT-141 from a men's wellness clinic deserve to know which they're getting.

The approved protocol is straightforward. 1.75 mg subcutaneous via the Vyleesi autoinjector, about 45 minutes before anticipated sexual activity, in the abdomen or thigh, sites rotated. No more than once per 24 hours. The label caps recommended monthly use around eight doses, primarily to limit cumulative MC1R exposure and the associated risk of skin pigmentation changes.

Off-label and compounded dosing is messier.

Compounded subcutaneous PT-141 from 503A pharmacies typically comes in multi-dose vials at concentrations that let providers titrate. Common doses in telehealth practice run 1 to 2 mg subcutaneous as needed. The intranasal route, studied in the early Phase 2 work at 7.5-20 mg, is no longer in clinical development and isn't an FDA-approved formulation, though some compounders still prepare it. Bioavailability intranasally is meaningfully lower than subcutaneous, which is why doses look so different on paper.

Troches - sublingual or buccal lozenges - appear in some telehealth prescriptions at around 2 mg. There's no peer-reviewed pharmacokinetic data for this route. We'd be cautious about it.

Worth flagging: compounded PT-141 is not Vyleesi. It hasn't been tested for sterility, potency, or stability the way an FDA-approved injectable has. That's not a claim that all compounded product is bad - reputable 503A pharmacies maintain high quality - but it's a category distinction that matters when something goes wrong.

Nausea is the headline.

In the Phase 3 program, around 40% of women on bremelanotide reported nausea, against 1.3% on placebo. Most of it was mild to moderate, peaked roughly two hours after dosing, and was the most common reason women stopped using the drug. A light meal beforehand seems to help. Some clinicians prescribe ondansetron for the first few doses. Many patients tolerate it; many don't.

Flushing showed up in about 20% of users (1.3% placebo). Headache, about 11% (1.9% placebo). Injection-site reactions, around 5%. These are mild and transient.

Vomiting happens, less often than nausea. Serious adverse events were small in number across the full development program of roughly 3,500 subjects. No deaths.

The one chronic-use concern is focal hyperpigmentation - small patches of darkened skin, often on the face or gums. At approved dosing (≤8 doses per month) it was rare. In a sub-study where subjects took up to 16 consecutive daily doses, more than a third developed pigmentation changes. That's well past labeled use, but it's the reason the monthly cap exists. Pigmentation may not fully reverse.

FDA's adverse event reporting system (FAERS) has logged 735 reports of chronic kidney disease and 556 reports of drug ineffective response associated with bremelanotide. FAERS is voluntary and uncontrolled - these signals don't establish causation, and the kidney signal in particular may reflect background disease in the user population rather than a drug effect. Worth knowing, not worth panicking over.

This is the part patients most need to understand.

Bremelanotide produces transient increases in blood pressure and decreases in heart rate after each dose. The mechanism runs through autonomic effects of MC4R activation. In the Phase 3 trials, mean systolic blood pressure rose about 1.9 mmHg per dose-day, with a peak rise around 2.8 mmHg at 4 to 8 hours post-dose. Effects resolved within roughly 12 hours.

Those are small numbers in aggregate. The catch is the individual variance. Some patients respond more than the mean. In a person with uncontrolled hypertension or pre-existing cardiovascular disease, a transient 10+ mmHg rise on top of an already-elevated baseline is not a trivial event.

That's why the FDA label contraindicates bremelanotide in uncontrolled hypertension and known cardiovascular disease, and why the standard of care is to check blood pressure before first use and ideally after.

It's also why combining bremelanotide with nitrates - the opposite vector, severe hypotension risk - is a hard no.

The label is specific. Contraindicated in uncontrolled hypertension and known cardiovascular disease. Avoid concurrent use with nitrates. Not for use in pregnancy. Not approved for postmenopausal women. Not approved for men.

Two drug interactions are documented. Bremelanotide lowers plasma concentrations of indomethacin and naltrexone, which means patients on either drug - common in chronic pain and addiction medicine - should be flagged. There's no clinically real interaction with alcohol. That's a real differentiator from flibanserin.

Sildenafil, tadalafil, and the rest of the PDE5-inhibitor class work peripherally. They block the enzyme that breaks down cGMP in penile tissue, which means an erection that's already starting gets to finish. They do nothing for desire. They do nothing if the upstream nitric oxide signal isn't there to begin with - which is why PDE5 inhibitors fail in some men.

PT-141 works centrally. It triggers the desire signal in the hypothalamus and, in men, initiates the downstream nitric oxide cascade from the top. That's a different drug doing a different job.

The two aren't really substitutes. For a man whose problem is mechanical - vascular ED with intact libido - a PDE5 inhibitor is the right first-line tool. For a man whose problem is upstream - low desire, PDE5-non-response, post-SSRI sexual dysfunction - bremelanotide is at least mechanistically plausible. The Phase 2 combination program is testing whether stacking them helps PDE5 non-responders. That's the interesting trial to watch.

Flibanserin came first. The FDA approved it for premenopausal HSDD in 2015, four years before Vyleesi. It's a daily oral pill, taken at bedtime, that works on serotonin and dopamine receptors.

The comparison goes like this:

Flibanserin requires daily dosing. Vyleesi is on-demand. For women whose desire problems are episodic - tied to anticipated intimacy rather than a chronic baseline - the on-demand profile fits the lived experience better.

Flibanserin's biggest practical liability is the alcohol interaction. The FDA initially required a black box warning against any alcohol use, later softened to "avoid alcohol within two hours before dosing." For a bedtime pill, this is awkward. Bremelanotide has no real alcohol interaction.

Flibanserin's efficacy is real but modest - typically one additional satisfying sexual event per month over placebo. Bremelanotide's effect is on the desire signal itself, measured on validated scales, not on event counts.

The tradeoffs run the other way too. Flibanserin doesn't cause 40% nausea rates. It doesn't carry a blood pressure warning. It doesn't risk skin pigmentation changes. For some patients, a daily pill is easier to integrate than an injection 45 minutes before anticipated sex.

Neither drug is a clear winner. They're tools with different shapes.

A short, honest checklist.

You might be a reasonable candidate if you're a premenopausal woman with diagnosed HSDD whose desire has changed from a normal baseline, who's already ruled out depression, medication side effects, and relationship factors, and whose blood pressure and cardiovascular history are clean.

You might be a reasonable off-label candidate if you're a man with low libido or PDE5-non-responsive ED, you've worked with a clinician to rule out hormonal causes (low testosterone, thyroid), and you're comfortable taking a drug whose evidence base in men is Phase 2 and observational rather than Phase 3.

You're probably not a candidate if you have uncontrolled hypertension or known cardiovascular disease, take nitrates, are pregnant or trying to be, are postmenopausal (the trials didn't include you and the safety profile in that group isn't established), or expect to use the drug more than about twice a week long-term.

You should walk away if your only source of PT-141 is an unregulated research-peptide vendor. The drug is real medicine. The grey market is not.

The honest summary: PT-141 is a legitimate drug with a narrow approved indication, a plausible off-label use case in men, a real side effect burden, and a cardiovascular asterisk that needs to be taken seriously. It works for some people. It doesn't work for others. The marketing - especially in the men's wellness space - runs ahead of the evidence. The science, where it exists, is solid.

Editorial note: This page is for informational purposes and doesn't constitute medical advice. Peptide therapy decisions, including any use of bremelanotide, should be made with a licensed healthcare provider familiar with your medical history, cardiovascular status, and current medications. Last reviewed by Dr. Sarah Henderson, MD, May 2026.